logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
INBX
Inhibrx Biosciences Inc.
86.21
1 x 86.74
1 x 87.28
bid
ask
-
1.40
1.60%
11:13 AM
timesize
Ytd9.13%
1y277.12%
85.28
day range
87.20
20.55
52 week range
155.29
Open85.92Prev Close87.61Low85.28High87.20Mkt Cap1.29B
Vol31.79KAvg Vol463.36KEPS-8.39P/E-10.44Forward P/E-14.76
Beta3.41Short Ratio10.24Inst. Own82.24%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1250-d Avg98.66200-d Avg81.861yr Est277.50

INBX News

Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act
seekingalpha.com
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act

Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 a

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
prnewswire.com
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Mil

SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nas

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
zacks.com
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice

Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investo

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
prnewswire.com
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarc

No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, O

Inhibrx Reports First Quarter 2026 Financial Results
prnewswire.com
Inhibrx Reports First Quarter 2026 Financial Results

SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "

Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
benzinga.com
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study

Inhibrx Biosciences, Inc. (NASDAQ:INBX) shares are trading higher on Monday as the company is report

Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
marketbeat.com
Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Biosciences NASDAQ: INBX reported interim randomized Phase 2 data for INBRX-106 in combinati

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
prnewswire.com
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate

Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
prnewswire.com
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First

– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT – SAN DIEGO, May 8, 2026 /PRNews

INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study
zacks.com
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study

Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates a

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue
seekingalpha.com
Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue

Inhibrx Biosciences, Inc. has surged nearly 40% amid rumors of Big Pharma interest in joint spinoffs

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
benzinga.com
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Inhibrx Biosciences Inc. (NASDAQ:INBX) is attracting interest from major drugmakers for its experime

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

GE Vernova, Boston Scientific, Intuitive Surgical And Other Big Stocks Moving Higher On Wednesday
benzinga.com
GE Vernova, Boston Scientific, Intuitive Surgical And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were higher, with the Dow Jones gaining over 350 points on Wednesday. GE Vernova shares

Dow Jumps Over 400 Points; Boeing Posts Upbeat Q1 Results
benzinga.com
Dow Jumps Over 400 Points; Boeing Posts Upbeat Q1 Results

US stocks rise, with Dow gaining over 400 points. Dow up 0.87%, NASDAQ up 0.70%, S&P 500 up 0.69

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say
reuters.com
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co , Germany's Merck KGaA a

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
prnewswire.com
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

SAN DIEGO, April 21, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
prnewswire.com
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Lin

– Event to be webcast live on Tuesday, April 21, 2026, at 1:30 p.m. PT – SAN DIEGO, April 20, 2026 /

Inhibrx Biosciences, Inc. (NASDAQ:INBX) Receives $150.00 Consensus Target Price from Analysts
defenseworld.net
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Receives $150.00 Consensus Target Price from Analysts

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) has received a consensus rating of "Hold"

SG Americas Securities LLC Invests $1.27 Million in Inhibrx Biosciences, Inc. $INBX
defenseworld.net
SG Americas Securities LLC Invests $1.27 Million in Inhibrx Biosciences, Inc. $INBX

SG Americas Securities LLC acquired a new position in Inhibrx Biosciences, Inc. (NASDAQ: INBX) in th

Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Inhibrx Biosciences (NASDAQ:INBX)
defenseworld.net
Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Inhibrx Biosciences (NASDAQ:INBX)

Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and CollPlant Biotechnologies (NASDAQ: CLGN - G

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
prnewswire.com
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the

7,388 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Dynamic Technology Lab Private Ltd
defenseworld.net
7,388 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd bought a new position in Inhibrx Biosciences, Inc. (NASDAQ: INBX)

Earnings Scheduled For November 14, 2025
benzinga.com
Earnings Scheduled For November 14, 2025

Ford, Inhibrx Biosciences, Comfort Systems, Western Union And Other Big Stocks Moving Higher On Friday
benzinga.com
Ford, Inhibrx Biosciences, Comfort Systems, Western Union And Other Big Stocks Moving Higher On Frid
benzinga.com
Stocks That Hit 52-Week Lows On Monday

  During Monday's trading, 1214 companies set new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Highs On Friday

  Friday's session saw 466 companies set new 52-week highs.